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Thrombolysis in cardiac arrest:
Initial enthusiasm tempered
We read with great interest the comprehensive
review advocating thrombolysis during cardiopul-
monary resuscitation conducted by Professor
Mysiak and co-workers [1]. However, we feel
obliged to mention that an important contribution
in this field was made last year.
At the World Congress of Cardiology 2006 in
Barcelona, the eagerly awaited results of the
Thrombolysis in Cardiac Arrest (TROICA) trial
were reported [2]. This prospective, randomized,
double-blind, placebo-controlled study was set up
to determine whether thrombolysis benefits in the
cardiac arrest scenario extend beyond the approved
indications such as ST-elevation myocardial infarc-
tion and massive pulmonary embolism. One thou-
sand and fifty patients with a witnessed cardiac ar-
rest of presumed cardiac origin were randomized
out of hospital to receive either a weight-adjusted
dose of tenecteplase or placebo after the first dose
of a vasopressor. Patients were enrolled in the tri-
al if they were at least 18 years of age and either if
basic life support had been started within 10 min of
onset and had been performed up to 10 min or if
advanced life support had been started within 10 min
of onset of cardiac arrest. The investigated drug or
placebo was given by paramedics at the same time
as cardiopulmonary resuscitation. The primary end-
point of the study was the 30-day survival rate, and
the co-primary endpoint was hospital admission.
Secondary endpoints were the return of spontane-
ous circulation, survival after 24 hours and surviv-
al until hospital discharge. Safety endpoints includ-
ed major bleeding complications and symptomatic
intracranial haemorrhage [3].
As indicated in Table 1, tenecteplase failed to
improve survival in cardiac arrest patients. Never-
theless, despite the lack of difference in any of the
efficacy endpoints, thrombolysis administration was
safe, and no significant increase in rates of sympto-
matic intracranial haemorrhage or major bleeding
between the two groups were observed.
The negative result of the trial does not nec-
essarily mean that thrombolysis is ineffective as
an adjunctive approach to cardiopulmonary resus-
citation. Contrary to the TROICA investigators,
Li et al. [4], in a recent meta-analysis including
926 patients from eight studies, concluded that
thrombolytic agents, when given during cardiop-
ulmonary resuscitation, significantly improved
the rate of return of spontaneous circulation,
24-hour survival, survival to discharge and long-
term neurological function. Despite these facts,
thrombolysis recipients were at an increased risk
of severe bleeding.
Similarly to the TROICA findings, in a post hoc
analysis of the large randomized trial comparing
vasopressin with epinephrine in out-of-hospital car-
diac arrest, the use of thrombolysis did not confer
any advantage in terms of hospital admission and
discharge rates after adjustment for confounding
variables [5]. Of note, a significantly higher crude
rate of hospital admission (45.5% vs. 32.7%, p = 0.01)
and a trend towards higher crude hospital discharge
rate (14.1% vs. 9.5%, p = 0.14) were noticed in the
thrombolysis arm. These differences may reflect
the worse baseline characteristics (older age, small-
er proportion of patients diagnosed with myocardial
infarction or pulmonary embolism, lower occurrence
Table 1. Results of the TROICA trial.
Endpoint Tenecteplase [%] Placebo [%] p
30-day survival 18.2 20.2 0.512
Hospital admission 59.0 59.5 0.931
Return of spontaneous circulation 59.6 59.2 0.977
24-hour survival 35.4 37.9 0.511
30-day survival or hospital discharge 18.8 21.0 0.481
Symptomatic intracranial haemorrhage 1.0 0.0 0.133
Major bleedings 8.9 7.4 0.528
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of witnessed cardiac arrest, lower presentation with
ventricular fibrillation as initial rhythm, longer esti-
mated interval between the collapse and the begin-
ning of basic or advanced life support) of the place-
bo group. Thrombolytic agents in this study were
given at the discretion of the emergency physician.
Furthermore, as reported by Mysiak at al., no evi-
dence of a beneficial effect of tissue plasminogen
activator was observed in the challenging popula-
tion of patients with cardiac arrest and pulseless
electrical activity of unknown or presumed cardio-
vascular cause unresponsive to initial therapy [6].
In the study, 233 subjects were randomly assigned
to receive a thrombolytic agent or placebo intrave-
nously in a double-blind fashion. One patient in the
tissue plasminogen activator group survived until
hospital discharge, as compared with none in the
placebo group (p = 0.99). The proportion of patients
with return of spontaneous circulation was 21.4%
in the tissue plasminogen activator group and 23.3%
in the placebo group (p = 0.85).
It should be also emphasised that most studies
suggesting advantageous effects of thrombolytics in
cardiac arrest possess major limitations
(non-randomized character, retrospective or obser-
vational design, small sample size) [7–9]. Other po-
tential explanations for the unexpected negligible
effect of thrombolysis in cardiac arrest include inap-
propriate timing and dosing regimen, possible nega-
tive interactions (vasopressors, acidosis, etc.), the
need for additional antithrombotic therapy and insuf-
ficiency of blow flow to bring the thrombolytic agent
to the thrombus in patients with prolonged cardiac
arrest. Moreover, patients with a quick return of
spontaneous circulation, a group with much more
favourable prognosis, were excluded from the
TROICA study [3]. On the other hand, the choice of
tenecteplase, a potent, fibrin-specific, single bolus-
dosing drug with excellent pharmacokinetic profile,
seems to be optimal in the resuscitation setting [10].
Finally, the obtained evidence does not sup-
port unrestricted use of thrombolysis in victims
of non-traumatic cardiac arrest. A subanalysis of
the TROICA trial would be helpful to identify sub-
jects who benefited from tenecteplase. Addition-
ally, the application of simple score systems
assessing the risk of pulmonary embolism and
myocardial infarction might enhance the selection
process.
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